Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002

Key clinical point: Neoadjuvant treatment with folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFOXIRI) plus selective radiotherapy offers better disease-free survival (DFS) than neoadjuvant chemoradiotherapy (CRT; fluorouracil plus radiotherapy) in patients with locally advanced rectal cancer (LARC).

Major finding: Patients receiving mFOLFOXIRI without routine radiotherapy vs CRT had a significantly higher 3-year DFS rate (87.6% vs 75.8%; hazard ratio 0.46; P  =  .037).

Study details: This phase 2 study, FORTUNE, studied propensity score-matched patients with LARC who received neoadjuvant mFOLFOXIRI without routine radiotherapy (n = 73) with those who received neoadjuvant CRT in the phase 3 FOWARC study (n = 73).

Disclosures: This study was sponsored by the National Key Research and Development Program of China and Science and Technology Program of Guangzhou. The authors declared no conflicts of interest.

Source: Zhang J et al. Neoadjuvant mfolfoxiri with selective radiotherapy in locally advanced rectal cancer: Long-term outcomes of phase II study and propensity-score matched comparison with chemoradiotherapy. Dis Colon Rectum. 2022 (Jul 12). Doi: 10.1097/DCR.0000000000002424

Key clinical point: Neoadjuvant treatment with folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFOXIRI) plus selective radiotherapy offers better disease-free survival (DFS) than neoadjuvant chemoradiotherapy (CRT; fluorouracil plus radiotherapy) in patients with locally advanced rectal cancer (LARC).

Major finding: Patients receiving mFOLFOXIRI without routine radiotherapy vs CRT had a significantly higher 3-year DFS rate (87.6% vs 75.8%; hazard ratio 0.46; P  =  .037).

Study details: This phase 2 study, FORTUNE, studied propensity score-matched patients with LARC who received neoadjuvant mFOLFOXIRI without routine radiotherapy (n = 73) with those who received neoadjuvant CRT in the phase 3 FOWARC study (n = 73).

Disclosures: This study was sponsored by the National Key Research and Development Program of China and Science and Technology Program of Guangzhou. The authors declared no conflicts of interest.

Source: Zhang J et al. Neoadjuvant mfolfoxiri with selective radiotherapy in locally advanced rectal cancer: Long-term outcomes of phase II study and propensity-score matched comparison with chemoradiotherapy. Dis Colon Rectum. 2022 (Jul 12). Doi: 10.1097/DCR.0000000000002424

Key clinical point: Neoadjuvant treatment with folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFOXIRI) plus selective radiotherapy offers better disease-free survival (DFS) than neoadjuvant chemoradiotherapy (CRT; fluorouracil plus radiotherapy) in patients with locally advanced rectal cancer (LARC).

Major finding: Patients receiving mFOLFOXIRI without routine radiotherapy vs CRT had a significantly higher 3-year DFS rate (87.6% vs 75.8%; hazard ratio 0.46; P  =  .037).

Study details: This phase 2 study, FORTUNE, studied propensity score-matched patients with LARC who received neoadjuvant mFOLFOXIRI without routine radiotherapy (n = 73) with those who received neoadjuvant CRT in the phase 3 FOWARC study (n = 73).

Disclosures: This study was sponsored by the National Key Research and Development Program of China and Science and Technology Program of Guangzhou. The authors declared no conflicts of interest.

Source: Zhang J et al. Neoadjuvant mfolfoxiri with selective radiotherapy in locally advanced rectal cancer: Long-term outcomes of phase II study and propensity-score matched comparison with chemoradiotherapy. Dis Colon Rectum. 2022 (Jul 12). Doi: 10.1097/DCR.0000000000002424

Key clinical point: Adding high-dose vitamin C to first-line chemotherapy does not significantly improve progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) but may benefit patients with RAS mutation.

Major finding: Patients who received high-dose vitamin C plus FOLFOX ± bevacizumab and those who received FOLFOX ± bevacizumab had a similar median PFS (8.6 and 8.3 months, respectively; hazard ratio [HR] 0.86; P  =  .1); however, those with RAS mutation treated with high-dose vitamin C plus FOLFOX ± bevacizumab vs FOLFOX ± bevacizumab had a significantly longer PFS (9.2 vs 7.8 months; HR 0.67; P  =  .01).

Study details: Findings are from a multicenter, phase 3 study that included 442 chemotherapy-naive patients with mCRC who were randomly assigned to receive FOLFOX ± bevacizumab or high-dose vitamin C plus FOLFOX ± bevacizumab.

Disclosures: This study was sponsored by the Sun Yat-sen University Clinical Research 5010 Program, China, among others. The authors declared no conflicts of interest.

Source: Wang F et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Clin Cancer Res. 2022 (Aug 5). Doi: 10.1158/1078-0432.CCR-22-0655

Key clinical point: Adding high-dose vitamin C to first-line chemotherapy does not significantly improve progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) but may benefit patients with RAS mutation.

Major finding: Patients who received high-dose vitamin C plus FOLFOX ± bevacizumab and those who received FOLFOX ± bevacizumab had a similar median PFS (8.6 and 8.3 months, respectively; hazard ratio [HR] 0.86; P  =  .1); however, those with RAS mutation treated with high-dose vitamin C plus FOLFOX ± bevacizumab vs FOLFOX ± bevacizumab had a significantly longer PFS (9.2 vs 7.8 months; HR 0.67; P  =  .01).

Study details: Findings are from a multicenter, phase 3 study that included 442 chemotherapy-naive patients with mCRC who were randomly assigned to receive FOLFOX ± bevacizumab or high-dose vitamin C plus FOLFOX ± bevacizumab.

Disclosures: This study was sponsored by the Sun Yat-sen University Clinical Research 5010 Program, China, among others. The authors declared no conflicts of interest.

Source: Wang F et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Clin Cancer Res. 2022 (Aug 5). Doi: 10.1158/1078-0432.CCR-22-0655

Key clinical point: Adding high-dose vitamin C to first-line chemotherapy does not significantly improve progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) but may benefit patients with RAS mutation.

Major finding: Patients who received high-dose vitamin C plus FOLFOX ± bevacizumab and those who received FOLFOX ± bevacizumab had a similar median PFS (8.6 and 8.3 months, respectively; hazard ratio [HR] 0.86; P  =  .1); however, those with RAS mutation treated with high-dose vitamin C plus FOLFOX ± bevacizumab vs FOLFOX ± bevacizumab had a significantly longer PFS (9.2 vs 7.8 months; HR 0.67; P  =  .01).

Study details: Findings are from a multicenter, phase 3 study that included 442 chemotherapy-naive patients with mCRC who were randomly assigned to receive FOLFOX ± bevacizumab or high-dose vitamin C plus FOLFOX ± bevacizumab.

Disclosures: This study was sponsored by the Sun Yat-sen University Clinical Research 5010 Program, China, among others. The authors declared no conflicts of interest.

Source: Wang F et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Clin Cancer Res. 2022 (Aug 5). Doi: 10.1158/1078-0432.CCR-22-0655

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) reported fatigue, and the degree of fatigue had a significant impact on their disease severity and physical functionality.

Major finding: The majority of patients with PsA (78.3%) reported fatigue. Patients with higher fatigue scores reported more severe disease, greater pain levels, and higher tender/swollen joint count (all P < .001). Higher fatigue scores were associated with worse physical functioning and higher overall work impairment (both P < .001).

Study details: Findings are from an analysis of an independent, cross-sectional, multinational, real-world survey, Adelphi Real World Spondyloarthritis (SpA) IV Disease Specific Programme, including 831 patients with PsA.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Three authors declared being employees of Janssen and shareholders of Janssen/Johnson & Johnson. Four authors declared being employees of Adelphi Real World. Other authors declared receiving grants of serving as consultants for several sources, including Janssen.

Source: Gossec L et al. Impact of fatigue on health-related quality of life and work productivity in psoriatic arthritis: Findings from a real-world survey. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.211288

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) reported fatigue, and the degree of fatigue had a significant impact on their disease severity and physical functionality.

Major finding: The majority of patients with PsA (78.3%) reported fatigue. Patients with higher fatigue scores reported more severe disease, greater pain levels, and higher tender/swollen joint count (all P < .001). Higher fatigue scores were associated with worse physical functioning and higher overall work impairment (both P < .001).

Study details: Findings are from an analysis of an independent, cross-sectional, multinational, real-world survey, Adelphi Real World Spondyloarthritis (SpA) IV Disease Specific Programme, including 831 patients with PsA.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Three authors declared being employees of Janssen and shareholders of Janssen/Johnson & Johnson. Four authors declared being employees of Adelphi Real World. Other authors declared receiving grants of serving as consultants for several sources, including Janssen.

Source: Gossec L et al. Impact of fatigue on health-related quality of life and work productivity in psoriatic arthritis: Findings from a real-world survey. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.211288

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) reported fatigue, and the degree of fatigue had a significant impact on their disease severity and physical functionality.

Major finding: The majority of patients with PsA (78.3%) reported fatigue. Patients with higher fatigue scores reported more severe disease, greater pain levels, and higher tender/swollen joint count (all P < .001). Higher fatigue scores were associated with worse physical functioning and higher overall work impairment (both P < .001).

Study details: Findings are from an analysis of an independent, cross-sectional, multinational, real-world survey, Adelphi Real World Spondyloarthritis (SpA) IV Disease Specific Programme, including 831 patients with PsA.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Three authors declared being employees of Janssen and shareholders of Janssen/Johnson & Johnson. Four authors declared being employees of Adelphi Real World. Other authors declared receiving grants of serving as consultants for several sources, including Janssen.

Source: Gossec L et al. Impact of fatigue on health-related quality of life and work productivity in psoriatic arthritis: Findings from a real-world survey. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.211288

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1